CompletedNCT03374475
How JNJ-42847922 May Affect Depression Symptoms
About this title
Read the official source —Medication studyAges 18–55Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- San Diego and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: January 5, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 140
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States, United Kingdom, Belgium, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03374475
- Official title
Show the full official title
An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedSan Diego, United States · San Marcos, United States · Miami, United States
10 more locations
- Mechelen, Belgium
- Merksem, Belgium
- Berlin, Germany
- Hanover, Germany
- Schwerin, Germany
- Leiden, Netherlands
- Blackpool, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-42847922 20mg, JNJ-42847922 40mg and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
